Day One Biopharmaceuticals, Inc. (DAWN) Stock
Day One Biopharmaceuticals, Inc.
Company profile
Day One Biopharmaceuticals reported revenue of $131.16 million for fiscal year 2024, and a net loss of $95.50 million. That is a net profit margin of -72.8% for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was $39.80 million, down 57.6% from a year before. In Q3 2025 it reported a net loss of $19.73 million, against net income of $37.04 million a year earlier.
What stands out
- It spent $227.70 million on research and development in fiscal year 2024, more than its revenue.
Figures from company filings; latest fiscal year ended December 31, 2024.
Largest shareholders
- Access Industries, Inc. (New York)12.76%
- Fidelity Management & Research Co. LLC11.19%
- BlackRock Advisors LLC8.90%
- Atlas Venture Life Science Advisors LLC6.34%
- Vanguard Fiduciary Trust Co.5.70%
Share of the company, as of November 8, 2025
In the news
- Day One Completes Acquisition of Mersana Therapeutics
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
- Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
- Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
How much revenue does Day One Biopharmaceuticals make?
Day One Biopharmaceuticals reported $131.16 million in revenue for fiscal year 2024. In Q3 2025 revenue was $39.80 million.
What companies are similar to Day One Biopharmaceuticals?
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY), Revolution Medicines, Inc. (RVMD), Exelixis, Inc. (EXEL).
How much does Day One Biopharmaceuticals spend on research and development?
Research and development by fiscal year: FY2020, $9.10 million; FY2021, $43.58 million; FY2022, $85.62 million; FY2023, $130.52 million; FY2024, $227.70 million.
Data as of .
How to cite: DataPorium, “Day One Biopharmaceuticals, Inc. (DAWN)”, data as of Nov 8, 2025, https://dataporium.tech/stocks/DAWN